Table 1.
Baseline demographic and clinical characteristics of the studied patients
| Variable | LC with HCC n = 37 |
LC n = 30 |
P-value | |
|---|---|---|---|---|
| Age (years) | ||||
| Mean ±SD | 64.11 ±8.09 | 61.63 ±6.91 | 0.86 | |
| Median (range) | 64 (48-84) | 61.5 (43-77) | ||
| Gender, n (%) | ||||
| Female | 9 (24.32) | 15 (50) | 0.03 | |
| Male | 28 (75.68) | 15 (50) | ||
| BMI | ||||
| Mean ±SD | 32.66 ±4.79 | 31.22 ±5.7 | 0.88 | |
| Median (range) | 32 (24-44) | 31.6 (23-44.7) | ||
| Diabetes mellitus, n (%) | 8 (21.62) | 13 (43.33) | 0.06 | |
| Hypertension, n (%) | 7 (18.92) | 9 (30) | 0.29 | |
| Smoking, n (%) | 12 (32.43) | 5 (16.67) | 0.14 | |
| UGIB, n (%) | 7 (18.92) | 18 (60) | 0.001 | |
| Hepatic encephalopathy, n (%) | 7 (18.92) | 16 (53.33) | 0.003 | |
| Jaundice, n (%) | 10 (27.03) | 11 (36.67) | 0.39 | |
| Ascites, n (%) | 12 (32.43) | 16 (53.33) | 0.09 | |
| History of DAAs, n (%) | 30 (81.08) | 29 (96.67) | 0.07 | |
| Child class, n (%) | ||||
| A | 17 (45.95) | 3 (10) | 0.006 | |
| B | 12 (32.43) | 16 (53.33) | ||
| C | 8 (21.62) | 11 (36.67) | ||
| MELD score | ||||
| Mean ±SD | 14 ±7.15 | 15.06 ±6.72 | 0.35 | |
| Median (range) | 11 (6-36) | 13 (7-30) | ||
LC – liver cirrhosis, HCC – hepatocellular carcinoma, BMI – body mass index, UGIB – upper gastrointestinal bleeding, DAAs – direct-acting antivirals, MELD – model for end-stage liver disease